Physitrack Q1 2024: Strong ARR growth - Redeye

Redeye comments on Physitrack’s soild Q1 figures, which were in line with our expectations. Highlights include quarter-on-quarter growth, an annual recurring revenue (ARR) increase of 15% y/y, positive FCF, and Software as a Service (SaaS) revenues now constituting 80% (71%) of total revenues. Consequently, we anticipate moderate adjustments to our near-term estimates and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1005464/physitrack-q1-2024-strong-arr-growth?utm_source=finwire&utm_medium=RSS